1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Mosunetuzumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 1 mg / vial
  • 1.3.3 30 mg / vial
• 1.4 Market Analysis by Route of Administration
  • 1.4.1 Overview: Global Mosunetuzumab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.4.2 Intravenous Infusion
  • 1.4.3 Subcutaneous Injection
• 1.5 Market Analysis by Combination Therapy
  • 1.5.1 Overview: Global Mosunetuzumab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032
  • 1.5.2 Mosunetuzumab In Combination With Polatuzumab Vedotin 莫妥珠单抗联合用药的临床试验数据 莫妥珠单抗联合用药的作用机制 莫妥珠单抗联合用药的常见副作用有哪些？
  • 1.5.3 Mosunetuzumab In Combination With Lenalidomide
• 1.6 Market Analysis by Production Technology
  • 1.6.1 Overview: Global Mosunetuzumab Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
  • 1.6.2 Innovator
  • 1.6.3 Generic
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Mosunetuzumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Relapsed or Refractory Follicular Lymphoma
  • 1.7.3 Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • 1.7.4 Other Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
• 1.8 Global Mosunetuzumab Market Size & Forecast
  • 1.8.1 Global Mosunetuzumab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Mosunetuzumab Sales Quantity (2021-2032)
  • 1.8.3 Global Mosunetuzumab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Roche
  • 2.1.1 Roche Details
  • 2.1.2 Roche Major Business
  • 2.1.3 Roche Mosunetuzumab Product and Services
  • 2.1.4 Roche Mosunetuzumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Roche Recent Developments/Updates

3 Competitive Environment: Mosunetuzumab by Manufacturer

• 3.1 Global Mosunetuzumab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Mosunetuzumab Revenue by Manufacturer (2021-2026)
• 3.3 Global Mosunetuzumab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Mosunetuzumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Mosunetuzumab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Mosunetuzumab Manufacturer Market Share in 2025
• 3.5 Mosunetuzumab Market: Overall Company Footprint Analysis
  • 3.5.1 Mosunetuzumab Market: Region Footprint
  • 3.5.2 Mosunetuzumab Market: Company Product Type Footprint
  • 3.5.3 Mosunetuzumab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Mosunetuzumab Market Size by Region
  • 4.1.1 Global Mosunetuzumab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Mosunetuzumab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Mosunetuzumab Average Price by Region (2021-2032)
• 4.2 North America Mosunetuzumab Consumption Value (2021-2032)
• 4.3 Europe Mosunetuzumab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Mosunetuzumab Consumption Value (2021-2032)
• 4.5 South America Mosunetuzumab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Mosunetuzumab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Mosunetuzumab Sales Quantity by Type (2021-2032)
• 5.2 Global Mosunetuzumab Consumption Value by Type (2021-2032)
• 5.3 Global Mosunetuzumab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Mosunetuzumab Sales Quantity by Application (2021-2032)
• 6.2 Global Mosunetuzumab Consumption Value by Application (2021-2032)
• 6.3 Global Mosunetuzumab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Mosunetuzumab Sales Quantity by Type (2021-2032)
• 7.2 North America Mosunetuzumab Sales Quantity by Application (2021-2032)
• 7.3 North America Mosunetuzumab Market Size by Country
  • 7.3.1 North America Mosunetuzumab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Mosunetuzumab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Mosunetuzumab Sales Quantity by Type (2021-2032)
• 8.2 Europe Mosunetuzumab Sales Quantity by Application (2021-2032)
• 8.3 Europe Mosunetuzumab Market Size by Country
  • 8.3.1 Europe Mosunetuzumab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Mosunetuzumab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Mosunetuzumab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Mosunetuzumab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Mosunetuzumab Market Size by Region
  • 9.3.1 Asia-Pacific Mosunetuzumab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Mosunetuzumab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Mosunetuzumab Sales Quantity by Type (2021-2032)
• 10.2 South America Mosunetuzumab Sales Quantity by Application (2021-2032)
• 10.3 South America Mosunetuzumab Market Size by Country
  • 10.3.1 South America Mosunetuzumab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Mosunetuzumab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Mosunetuzumab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Mosunetuzumab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Mosunetuzumab Market Size by Country
  • 11.3.1 Middle East & Africa Mosunetuzumab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Mosunetuzumab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Mosunetuzumab Market Drivers
• 12.2 Mosunetuzumab Market Restraints
• 12.3 Mosunetuzumab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Mosunetuzumab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Mosunetuzumab
• 13.3 Mosunetuzumab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Mosunetuzumab Typical Distributors
• 14.3 Mosunetuzumab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Mosunetuzumab market size was valued at US$ 99 million in 2025 and is forecast to a readjusted size of US$ 238 million by 2032 with a CAGR of 7.5% during review period.
In 2025, global Mosunetuzumab production reached approximately 3,200units.Mosunetuzumab is a fully human IgG1 subtype CD20/CD3 bispecific monoclonal antibody that mainly targets the CD20 antigen on the surface of B lymphocytes and the CD3 receptor on the surface of T lymphocytes. It bridges tumor B cells and cytotoxic T cells to activate T cell-mediated immune killing, thereby specifically eliminating malignant B cells. Administered via intravenous injection, this drug is mainly indicated for the treatment of B-cell non-Hodgkin lymphomas such as relapsed or refractory follicular lymphoma. As a tumor immunotherapeutic agent, it features high targeting specificity and distinct antitumor activity.
Mosunetuzumab, as the world’s first CD20/CD3 bispecific antibody approved for relapsed or refractory follicular lymphoma, has established a core position in the later-line treatment of indolent lymphomas by virtue of its innovative T-cell bridging mechanism, high remission rate and favorable safety profile. Its “off-the-shelf” nature significantly improves treatment accessibility and avoids the individualized preparation cycle required for CAR-T therapies. With the approval of the subcutaneous formulation, administration convenience has been greatly enhanced, further promoting the popularization of its clinical application. In the market, the drug has been included in authoritative clinical guidelines both at home and abroad, with its indications continuously expanding to front-line settings and combination regimens under active exploration. In the global competitive landscape, it forms differentiated complementation with similar bispecific antibodies, ADCs and CAR-T products, occupying a stable market share thanks to its structural advantages and long-term therapeutic benefits. As a key focus of global layout, the Chinese market is expected to witness continuous improvement in accessibility and remarkable growth potential with domestic approval and potential insurance coverage. Overall, mosunetuzumab is reshaping the treatment landscape of follicular lymphoma and is expected to move from later-line to front-line therapy in the future, becoming a key regimen contributing to functional cure.
This report is a detailed and comprehensive analysis for global Mosunetuzumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Mosunetuzumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mosunetuzumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mosunetuzumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Mosunetuzumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mosunetuzumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mosunetuzumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Mosunetuzumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
1 mg / vial
30 mg / vial
Market segment by Route of Administration
Intravenous Infusion
Subcutaneous Injection
Market segment by Combination Therapy
Mosunetuzumab In Combination With Polatuzumab Vedotin 莫妥珠单抗联合用药的临床试验数据 莫妥珠单抗联合用药的作用机制 莫妥珠单抗联合用药的常见副作用有哪些？
Mosunetuzumab In Combination With Lenalidomide
Market segment by Production Technology
Innovator
Generic
Market segment by Application
Relapsed or Refractory Follicular Lymphoma
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Other Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Major players covered
Roche
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Mosunetuzumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Mosunetuzumab, with price, sales quantity, revenue, and global market share of Mosunetuzumab from 2021 to 2026.
Chapter 3, the Mosunetuzumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Mosunetuzumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Mosunetuzumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Mosunetuzumab.
Chapter 14 and 15, to describe Mosunetuzumab sales channel, distributors, customers, research findings and conclusion.